Number of views:
Approved date: January 29, 2007
Date of revision: October 1, 2010
November 30, 2015
Sulpiride Tablet Instruction
Please read the instructions carefully and use them under the guidance of a physician.
Common name: sulpiride tablets
English name: Sulpiride Tablets
Pinyin: Shubili Pian
[Ingredients] The main ingredients of this product are: sulpiride. Its chemical name is: N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-(aminosulfonyl)benzamide.
Molecular formula: C15H23N3O4S
Molecular weight: 341.42
【Properties】 This product is a white film.
[Indications] For schizophrenia, simple, paranoid, nervous, and chronic schizophrenia, solitude, withdrawal, apathy. It has a certain effect on depressive symptoms. Other uses include vomiting.
Oral treatment of schizophrenia, starting dose of 100mg (1 tablet), 2 to 3 times a day, gradually increased to the therapeutic amount of 600 ~ 1200mg (6 ~ 12 tablets) a day, the maintenance dose is 200 ~ 600mg a day (2 ~6 pieces). Stop vomiting, once 100~200mg (1~2 tablets), 2~3 times a day. Children over the age of 6 are converted to adult doses and should start with a small dose and slowly increase the dose.
1, common insomnia, early awakening, headache, irritability, fatigue, loss of appetite and so on. Anti-cholinergic adverse reactions such as dry mouth, blurred vision, tachycardia, dysuria and constipation may occur.
2. Extrapyramidal reactions may occur when the dose is greater than 600 mg per day, such as tremor, stiffness, salivation, bradykinesia, sedation, and acute dystonia.
3, more caused by increased plasma prolactin concentration, may be related to symptoms: galactorrhea, men's feminine breast, menstrual disorders, amenorrhea, weight gain.
4, ECG abnormalities and liver function damage can occur.
5, a small number of patients may have excitement, agitation, sleep disorders or elevated blood pressure.
6, a large number of long-term medication can cause delayed dyskinesia.
[Contraindications] Patients with pheochromocytoma, hypertensive patients, severe cardiovascular disease and severe liver disease, who are allergic to this product are prohibited.
1, with cardiovascular disease (such as: arrhythmia, myocardial infarction, conduction abnormalities) should be used with caution.
2. In the presence of tardive dyskinesia, all antipsychotics should be discontinued.
3. Allergic skin rashes and malignant symptoms should be discontinued immediately and treated accordingly.
4, basal ganglia lesions, Parkinson's syndrome, severe central nervous system inhibition state with caution.
5, liver and kidney dysfunction should be reduced.
6, with caution in patients with epilepsy.
[Pregnant women and lactating women] Pregnant women should be used with caution and should be used at lower doses. Lactating women should stop breastfeeding during the use of this product.
[Children's medication] use with caution.
[Geriatric Use] Elderly patients should start with a small dose and slowly increase the dose.
[Drug interaction] In addition to clozapine, almost all antipsychotics and central inhibitors, such as in combination with this product, can enhance central inhibition, and should be fully noted.
Symptoms of poisoning:
1. Central nervous system symptoms: severe disturbance of consciousness, from lethargy, inattention to drowsiness, and finally into a coma. During the examination, the pupil was found to be reduced and the response to light was slow. At the same time, the central body temperature is too low.
2, cardiovascular system symptoms: orthostatic hypotension, increased heart rate, pulse count, occasional arrhythmia, severe hypovolemic shock.
3, blood system symptoms: neutropenia, allergic purpura.
Treatment: gastric lavage, catharsis, infusion. Symptomatic treatment and supportive therapy are given according to the condition.
[Pharmacology and Toxicology] This product is a benzamide antipsychotic drug. It is characterized by selective blocking of the dopamine (DA2) receptor in the limbic system of the midbrain. It has less effect on other transmitters and has an anticholinergic effect. Light, no obvious sedative and anti-excitatory action, this product also has a strong antiemetic and inhibit gastric secretion.
[Pharmacokinetics] This product is absorbed from the gastrointestinal tract. It can reach the peak of blood concentration in 2 hours. The product is orally administered for 48 hours. 30% of the oral dose is discharged from the urine, and part of it is discharged from the feces. The plasma half-life (t1/2) is 8-9 hours. Animal experiments show that the product can enter the cord blood circulation through the placental barrier. This product is mainly excreted by the kidneys. Can be discharged from breast milk.
[Storage] shading, sealed (10 ~ 30 ° C) preservation.
[Package] medicinal plastic bottles, 100 tablets per bottle.
[Validity Period] 24 months
[Executive Standards] "Chinese Pharmacopoeia" 2015 Edition 2
[Approval No.] National Drug Standard H44021373
Company Name: Guangdong Pi Di Pharmaceutical Co., Ltd.
Production address: No. 66, Pidi Avenue, Yueshan Town, Kaiping City, Guangdong Province
Postal code: 529331
Phone number: (0750) 2789348
400-8899-328 (National Service Phone)
Fax number: (0750) 2789348
COPYRIGHT GUANGDONG BIDI PHARMACEUTICAL CO., LTD. © 2015 POWERED BY WWW.300.CN